- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Hopes to Accelerate Biosimilar Supplement Reviews
The agency will now review and act on original 351(k) biologics license application (BLA) supplements with clinical data within a 6-month time frame. Originally, such supplements had a 10-month goal date for review. In addition, applicants can now request the FDA refrain from taking action on supplements of 351(k) BLAs before a certain date.
On February 6, the US FDA published a new draft guidance entitled “Biosimilars and Interchangeable Biosimilars: Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed.”
The agency will now review and act on original 351(k) biologics license application (BLA) supplements with clinical data within a 6-month time frame. Originally, such supplements had a 10-month goal date for review. In addition, applicants can now request the FDA refrain from taking action on supplements of 351(k) BLA before a certain date.
“As part of its review, FDA assesses the manufacturing process and the manufacturer’s strategy to control within-product variations. These control strategies are put in place to help ensure that manufacturers produce biological products with consistent clinical performance,” the FDA states.
The draft provides recommendations to applicants who are seeking licenses for a proposed biosimilar or interchangeable application supplements, with the aim of expediting reviews for biosimilars supplements. It can also be used to update initial biosimilar approvals when it is for fewer than all the reference product’s approved conditions.
According to the guidance, biosimilars or interchangeable products cannot be licensed for an indication by the FDA if they are protected by orphan drug exclusivity or pediatric exclusivity, until that exclusivity expires. Applicants can submit a supplement to the licensed 351(k) BLA for the previously protected indication once any exclusivity or patent expires.
The FDA recommends that when possible, an applicant who is seeking licensure for a proposed interchangeable product also seek licensure for all of the reference product’s licensed conditions of use.
Proposed biosimilar labeling will be dependent on whether the applicant seeks licensure for all or fewer of the conditions of use licensed for the reference product, according to RAPS.
Electronic or written comments on the draft can be submitted until April 7, 2020, before the final version of the guidance is released.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
